×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Update on Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares of Commo
Yahoo Movies Canada
Update on Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares of Common Stock PRINCETON, N.J.--(BUSINESS...
3 days ago
Advaxis Executive Reshuffle Following Asset Sale - TipRanks.com
Tipranks
Advaxis (ADXS) has provided an update. Ayala Pharmaceuticals, Inc. finalized a major asset sale on March 25, 2024, leading to the departure...
3 weeks ago
Advaxis spies merger with Ayala as route back to Nasdaq
Fierce Biotech
Advaxis spies merger with Ayala as route back to Nasdaq ... With $20 million on hand and the second part of a potentially registrational phase 2/3...
18 months ago
Advaxis enters merger deal with biotech firm Ayala
Pharmaceutical Technology
Ayala Pharmaceuticals has signed a definitive merger agreement with Advaxis, which discovers, develops and markets immunotherapies.
18 months ago
Advaxis completes merger to become Ayala Pharmaceuticals
NJBIZ
Monmouth Junction-based biotech firm Advaxis Inc. closed its previously announced merger with Ayala Pharmaceuticals Inc., based in Delaware.
15 months ago
Advaxis and Ayala Pharmaceuticals Enter into Merger Agreement
GlobeNewswire
Upon completion of the merger, Ayala stockholders will own approximately 62.5% of the combined company's outstanding common stock and Advaxis...
18 months ago
Advaxis and Ayala Merge to Hone In on Desmoid Tumors, Prostate Cancer
BioSpace
Advaxis and Ayala Pharmaceuticals entered a reverse merger deal to focus on two clinical-stage cancer therapies: AL102 for desmoid tumors...
18 months ago
Cancer treatment developers Ayala Pharmaceuticals and Advaxis complete merger - Philadelphia Business Journal
The Business Journals
Cancer treatment developers Ayala Pharmaceuticals and Advaxis complete merger ... Former Ayala CEO Roni Mamluk resigned as part of the company's...
15 months ago
Ayala Pharmaceuticals And Advaxis To Merge
Contract Pharma
To focus on the development of Ayala's lead program AL102 for the treatment of desmoid tumors and Advaxis's candidate ADXS-504 in prostate...
18 months ago